AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 8237086
Drug: Supine position
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supine position with liquid bolus (5 ml water)
Trial: 27393622
Drug: nab-paclitaxel with
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: nab-paclitaxel with concurrent bevacizumab followed by AC
Trial: 23424755
Drug: Lymphdiaral Basistropfen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lymphdiaral Basistropfen (verum) - 10 drops three times daily for 105 days
Trial: 23424755
Drug: Placebo -
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo - 10 drops three times daily for 105 days
Trial: 16110851
Drug: Drug therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug therapy (Propranolol + ISMN)
Trial: 12448042
Drug: Evidence-Based Medicine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evidence-Based Medicine (EBM)
Trial: 8520875
Drug: IL-2 treatment
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IL-2 treatment alone (41 patients)
Trial: 8520875
Drug: IL-2 treatment
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IL-2 treatment with interferon gamma (33 patients)
Trial: 2405326
Drug: EMLA cream
RxNorm normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EMLA cream (lidocaine/prilocaine) applied 1-75 minutes before CO2 laser treatment
Trial: 2405326
Drug: Placebo cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo cream applied 1-75 minutes before CO2 laser treatment
Trial: 649204
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg thrice daily for seven days
Trial: 649204
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 2400 mg
Trial: 649204
Drug: Two 2400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two 2400 mg doses on successive days
Trial: 649204
Drug: 2400 mg
RxNorm normalized name: pancreatin 2400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2400 mg dosages
Trial: 17130680
Drug: Omalizumab (150,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omalizumab (150, 225, 300, or 375mg) administered subcutaneously every 2 or 4 weeks
Trial: 12584276
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid (ASA) 150 mg/day for 4 weeks
Trial: 10675831
Drug: Conjugated estrogen-medrogestone
RxNorm normalized name: estrogens, conjugated (USP) / medrogestone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conjugated estrogen-medrogestone combination
Trial: 9116774
Drug: r-FSH with
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: r-FSH with LHRH agonist
Trial: 9116774
Drug: r-FSH without
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: r-FSH without LHRH agonist
Trial: 1439226
Drug: Breath-actuated metered
RxNorm normalized name: QVAR Redihaler 80 MCG/ACTUAT Breath-Actuated Metered Dose Inhaler, 120 ACTUAT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Breath-actuated metered dose inhaler (Aerolin in the Autohaler inhalation device)
Trial: 1439226
Drug: Standard press
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard press and breathe metered dose inhaler
Trial: 19118696
Drug: Ranibizumab (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranibizumab (0.3 mg or 0.5 mg)
Trial: 21626816
Drug: Cerebrolysin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cerebrolysin (50 ml)
Trial: 9027792
Drug: Cefuroxime 1.5
RxNorm normalized name: cefuroxime 1.5 GM Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefuroxime 1.5 g i.v. preoperatively and 250 mg i.p. in the first dialysis bag (1 litre fluid)
Trial: 8104044
Drug: Serazepine (CGS‐15040A)
RxNorm normalized name: Alkamide 101-cg
DrugBank: Coco diethanolamide (DB18828)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serazepine (CGS‐15040A) at doses greater than or equal to 10 mg
Trial: 3089950
Drug: Ordinary lithium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ordinary lithium carbonate (1.5 g)
Trial: 3089950
Drug: Sustained-release lithium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release lithium carbonate (1.8 g)
Trial: 27461133
Drug: Lactobacillus reuteri-containing
RxNorm normalized name: Lactobacillus reuteri-containing product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus reuteri-containing lozenges (≥108 CFU L. reuteri ATCC PTA 5289 and ≥108 CFU L. reuteri DSM 17938, consumed 2× daily for approx. 7 weeks)
Trial: 31157556
Drug: Lactobacillus reuteri-containing
RxNorm normalized name: Lactobacillus reuteri-containing product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus reuteri-containing lozenges
Trial: 27461133
Drug: Placebo (devoid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (devoid of L. reuteri)
Trial: 21677121
Drug: Free lutein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Free lutein (fL) 12.2 mg
Trial: 21677121
Drug: Lutein esters
RxNorm normalized name: lutein esters
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lutein esters (Le) 27 mg (equivalent to 13.5 mg free lutein)
Trial: 17307425
Drug: Unopposed estrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unopposed estrogen (conjugated estrogen, 0.625 mg)
Trial: 17307425
Drug: Estrogen +
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen + medroxyprogesterone acetate (MPA, 2.5 mg)
Trial: 17307425
Drug: Women who
RxNorm normalized name: Arthricare for Women Moisturizing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Women who took >80% of study medication
Trial: 12943952
Drug: Fluoxetine 20
RxNorm normalized name: fluoxetine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine 20 mg daily (flx20)
Trial: 12943952
Drug: Fluoxetine 40
RxNorm normalized name: fluoxetine 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine 40 mg daily (flx40)
Trial: 12943952
Drug: Fluoxetine 20
RxNorm normalized name: fluoxetine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine 20 mg plus buspirone 20 mg daily (flx20-plus-buspirone)
Trial: 10682871
Drug: Standard Purine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Purine soy formula (180 mg purines/L from RNA)
Trial: 10682871
Drug: Reduced Purine
RxNorm normalized name: Iron, reduced
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduced Purine soy formula (65 mg purines/L; 26 mg/L from RNA and 39 mg/L from ribonucleotides)
Trial: 9054254
Drug: Propofol plus
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol plus high-dose esmolol (bolus of 1 mg/kg, then 250 micrograms.kg-1.min-1)
Trial: 9054254
Drug: Propofol plus
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol plus low-dose esmolol (bolus of 0.5 mg/kg, then 50 micrograms.kg-1.min-1)
Trial: 8356866
Drug: High-flow anaesthesia
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-flow anaesthesia using a partial rebreathing system without carbon dioxide absorption (Mapleson D)
Trial: 8356866
Drug: Medium-flow anaesthesia
RxNorm normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium-flow anaesthesia using a circle system with carbon dioxide absorption
Trial: 8356866
Drug: Low-flow anaesthesia
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-flow anaesthesia using a circle system with carbon dioxide absorption
Trial: 2868255
Drug: Dietary manipulation
RxNorm normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dietary manipulation therapy
Trial: 31797330
Drug: Cognitive remediation-enabled
RxNorm normalized name: Enablex
DrugBank: Darifenacin (DB00496)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cognitive remediation-enabled cognitive behaviour therapy (CR-CBT)
Trial: 24748630
Drug: Golimumab (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Golimumab (50 mg or 100 mg) from week 24 onward
Trial: 23764521
Drug: Aripiprazole 2
RxNorm normalized name: aripiprazole 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aripiprazole 2 mg/day (Phase 1) and 5 mg/day (Phase 2)
Trial: 23764521
Drug: Aripiprazole 2
RxNorm normalized name: aripiprazole 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aripiprazole 2 mg/day (Phase 2)
Trial: 27111239
Drug: Alendronate (ALN)
RxNorm normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alendronate (ALN) 10 mg/day
Trial: 19580465
Drug: Alendronate (ALN)
RxNorm normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alendronate (ALN) 5 mg/day
Trial: 18664276
Drug: Tai Chi
RxNorm normalized name: Ma Chi Xian
DrugBank: Purslane (DB14327)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tai Chi (10 modified forms from classical Yang style Tai Chi), 60-minute sessions, twice weekly for 12 weeks
Trial: 18664276
Drug: Attention control
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Attention control (wellness education and stretching), 60-minute sessions, twice weekly for 12 weeks
Trial: 12607326
Drug: Lansoprazole 30
RxNorm normalized name: lansoprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 30 mg bid, Amoxicillin 750 mg bid, Clarithromycin 200 mg bid
Trial: 12607326
Drug: Lansoprazole 30
RxNorm normalized name: lansoprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 30 mg bid, Amoxicillin 750 mg bid, Clarithromycin 400 mg bid
Trial: 12607326
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg, Amoxicillin 750 mg bid, Clarithromycin 400 mg bid
Trial: 12607326
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg, Amoxicillin 1,000 mg, Clarithromycin 500 mg bid
Trial: 11391837
Drug: zalcitabine 2.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: zalcitabine 2.25 mg and saquinavir 1800 mg per day
Trial: 6509283
Drug: Phenobarbitone 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenobarbitone 30 mg
Trial: 6509283
Drug: Phenobarbitone 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenobarbitone 100 mg
Trial: 28722569
Drug: Annual mass
RxNorm normalized name: annual bluegrass pollen extract
DrugBank: Poa annua pollen (DB10353)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Annual mass azithromycin distributions (3 treatments during high-transmission season)
Trial: 28722569
Drug: Biannual mass
RxNorm normalized name: annual bluegrass pollen extract
DrugBank: Poa annua pollen (DB10353)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biannual mass azithromycin distributions (6 treatments: 3 during high-transmission season and 3 during low-transmission season)
Trial: 16964669
Drug: Interferon-alpha-2b treatment
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon-alpha-2b treatment during vaccination (Group A, 12 patients)
Trial: 16964669
Drug: Hepatitis B
RxNorm normalized name: HEPATITIS B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis B vaccine without interferon (Group B, 25 patients)
Trial: 9287255
Drug: Psychological treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychological treatment conditions for IBS
Trial: 8330445
Drug: L‐thyroxine therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L‐thyroxine therapy
Trial: 3090332
Drug: Bolus MMC
RxNorm normalized name: MMC
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bolus MMC with no further treatment (Group A)
Trial: 3090332
Drug: Oral futraful
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral futraful for one year without MMC induction (Group C)
Trial: 3090332
Drug: Bolus MMC
RxNorm normalized name: MMC
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bolus MMC injection and oral futraful (Group B)
Trial: 3090332
Drug: Bolus MMC
RxNorm normalized name: MMC
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bolus MMC and oral futraful for one year (Group B)
Trial: 30625042
Drug: Platelet-rich plasma
RxNorm normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platelet-rich plasma (PRP) patch treatments
Trial: 30625042
Drug: Platelet-derived patch
RxNorm normalized name: Platelet-derived growth factor BB, recombinant
DrugBank: Becaplermin (DB00102)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Platelet-derived patch treatment and PRP injection
Trial: 19501932
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment with vitamin K2 (VK; menatetrenone; 45 mg/day) and angiotensin-converting enzyme inhibitor (ACE-I; perindopril; 4 mg/day) for 36-48 months
Trial: 19501932
Drug: Vitamin K2
RxNorm normalized name: Vitamin K2
DrugBank: Menaquinone 6 (DB14936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin K2 (VK; menatetrenone; 45 mg/day)
Trial: 19501932
Drug: Angiotensin-converting enzyme
RxNorm normalized name: ACE - Angiotensin-converting enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin-converting enzyme inhibitor (ACE-I; perindopril; 4 mg/day)
Trial: 2475682
Drug: Sustained-release verapamil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release verapamil (240 mg once daily)
Trial: 28301686
Drug: Non-operative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-operative treatment with daily site-specific oral hygiene using fluoridated toothpaste, professional topical fluoride treatment, and dietary advice.
Trial: 23444228
Drug: Ipilimumab 3
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ipilimumab 3 mg/kg plus gp100 vaccine
Trial: 23444228
Drug: Ipilimumab 3
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ipilimumab 3 mg/kg plus placebo
Trial: 23400564
Drug: gp100 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gp100 vaccine plus placebo
Trial: 19725594
Drug: CNTO 528
RxNorm normalized name: Human monoclonal antibody targeting CC-chemokine ligand 2 (CNTO 888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CNTO 528 at 0.03 mg/kg
Trial: 19725594
Drug: CNTO 528
RxNorm normalized name: Human monoclonal antibody targeting CC-chemokine ligand 2 (CNTO 888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CNTO 528 at 0.09 mg/kg
Trial: 19725594
Drug: CNTO 528
RxNorm normalized name: Human monoclonal antibody targeting CC-chemokine ligand 2 (CNTO 888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CNTO 528 at 0.3 mg/kg
Trial: 19725594
Drug: CNTO 528
RxNorm normalized name: Human monoclonal antibody targeting CC-chemokine ligand 2 (CNTO 888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CNTO 528 at 0.9 mg/kg
Trial: 17724294
Drug: Atorvastatin 20
RxNorm normalized name: atorvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 20 mg/day (n = 43)
Trial: 17724294
Drug: Statin withdrawal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin withdrawal compared to non-randomized patients without previous statin therapy (n = 126)
Trial: 15134708
Drug: Hypertonic saline
RxNorm normalized name: ENTSOL Hypertonic Saline Nasal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypertonic saline injection into the right trapezius muscle
Trial: 15134708
Drug: Isotonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic saline injection into the right trapezius muscle
Trial: 15134708
Drug: Hypertonic saline
RxNorm normalized name: ENTSOL Hypertonic Saline Nasal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypertonic saline injection into the right temporalis muscle
Trial: 15134708
Drug: Isotonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic saline injection into the right temporalis muscle
Trial: 9728842
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg of intrathecal ropivacaine plus sufentanil 10 microg (R2)
Trial: 9728842
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg of intrathecal ropivacaine plus sufentanil 10 microg (R4)
Trial: 9728842
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg of intrathecal bupivacaine plus sufentanil 10 microg (B)
Trial: 29368880
Drug: Compression therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compression therapy group (N=20)
Trial: 23837278
Drug: Bupivacaine 0.5%
RxNorm normalized name: BUPivacaine 0.5% injectable kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 0.5% (10 mL)
Trial: 23334115
Drug: Ropivacaine 0.75%
RxNorm normalized name: ROPivacaine 0.75% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.75% (10 mL)
Trial: 18471341
Drug: lornoxicam (16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lornoxicam (16 mg, i.v.)
Trial: 16311286
Drug: Ephedrine 50
RxNorm normalized name: Ephedrine 50 MG Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ephedrine 50 mg in saline 0.9% w/v, 500 ml at 999 ml h(‐1)
Trial: 16311286
Drug: Phenylephrine 500
RxNorm normalized name: acetaminophen-phenylephrine 500 mg-5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylephrine 500 microg in saline 0.9% w/v, 500 ml at 999 ml h(‐1)
Trial: 8856257
Drug: Dialysis with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dialysis with dialysate containing 128 mEq/l sodium
Trial: 8856257
Drug: Dialysis with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dialysis with dialysate containing 137 mEq/l sodium
Trial: 8737627
Drug: 0.125 mg
RxNorm normalized name: digoxin 0.125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.125 mg brotizolam
Trial: 6527754
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg nitrazepam
Trial: 30148660
Drug: Children with
RxNorm normalized name: Pediaclear Childrens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Children with ADHD (no medication)
Trial: 21247745
Drug: Atenolol (after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (after one-week treatment)
Trial: 15988705
Drug: Simvastatin 10
RxNorm normalized name: simvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 10 mg/d
Trial: 15988705
Drug: Coadministration of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coadministration of raloxifene 60 mg/d and simvastatin 10 mg/d
Trial: 7572582
Drug: Mibefradil 100
RxNorm normalized name: mibefradil 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mibefradil 100 mg
Trial: 10336572
Drug: Control (baseline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (baseline beta-adrenoceptor blocker treatment)
Trial: 10336572
Drug: Mibefradil (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mibefradil (both doses)
Trial: 12097764
Drug: Ciprofloxacin 500
RxNorm normalized name: ciprofloxacin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 500 mg twice a day for 10 days
Trial: 7573719
Drug: Ciprofloxacin 500
RxNorm normalized name: ciprofloxacin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 500 mg twice a day for 14 days
Trial: 2007671
Drug: Topical immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical immunotherapy (diphenylcyclopropenone)
Trial: 2007671
Drug: Control (unilateral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (unilateral treatment side)
Trial: 7132464
Drug: Experimental clinics
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental clinics with age-specific checklists and weekly seminars
Trial: 29654498
Drug: Coffee robusta
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coffee robusta sachet dissolved in 100 ml of hot water
Trial: 29654498
Drug: 100 ml
RxNorm normalized name: PVC IV Bag 100 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 ml water only
Trial: 20035353
Drug: Traditional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional treatment (15 patients laparoscopic, 22 patients open)
Trial: 16160619
Drug: St John's
RxNorm normalized name: St john's wort
DrugBank: St. John's Wort (DB01323)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: St John's wort (900 mg/d)
Trial: 9176086
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg GTN (0.5 mg/ml)
Trial: 9176086
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg GTN (1 mg/ml)